Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1007/s11239-021-02398-3 http://scihub22266oqcxt.onion/10.1007/s11239-021-02398-3 33638018!7909731!33638018     free     free     free Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 235.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       J+Thromb+Thrombolysis 2021 ; 52 (3): 889-897 Nephropedia Template TP {{tp|p=33638018|t=2021. Stroke and presence of patent foramen ovale in sickle cell disease |pdf=|usr=}}{{33638018}} gab.com Text Stroke and presence of patent foramen ovale in sickle cell disease JO: J Thromb Thrombolysis http://www.kidney.de/pget.php?&tw=1&pmid=33638018 #FOAvip Sickle cell disease (SCD) is an inherited monogenic hemoglobinopathy characterized by formation of sickle erythrocytes under conditions of deoxygenation. Sickle erythrocytes can lead to thrombus formation and vaso-occlusive episodes that may result in hemolytic anemia, pain crisis and multiple organ damage. Moreover, SCD is characterized by endothelial damage, increased inflammatory response, platelet activation and aggravation, and activation of both the intrinsic and the extrinsic coagulation pathways. Cerebrovascular events constitute an important clinical complication of SCD. Children with SCD have a 300-fold higher risk of acute stroke and by the age of 45 about 25% of patients have suffered an overt stoke. Management and prevention of stroke in patients with SCD is not well defined. Moreover, the presence of patent foramen ovale (PFO) increases the risk of the occurrence of an embolic cerebrovascular event. The role of PFO closure and antiplatelet or anticoagulation therapy has not been well investigated. Moreover, during COVID-19 pandemic and taking into account the increased rates of thrombotic events and the difficulties in blood transfusion, management of SCD patients is even more challenging and difficult, since data are scarce regarding stroke occurrence and management in this specific population in the COVID-19 era. This review focuses on pathophysiology of stroke in patients with SCD and possible treatment strategies in the presence of PFO. Twit Text FOAVip Stroke and presence of patent foramen ovale in sickle cell disease ????J Thromb Thrombolysis http://www.kidney.de/pget.php?&tw=1&pmid=33638018 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33638018 #FOAvip English Wikipedia <ref>{{Cite pmid|33638018}}</ref> Stroke and presence of patent foramen ovale in sickle cell disease #MMPMID33638018 Aggeli C; Polytarchou K; Dimitroglou Y; Patsourakos D; Delicou S; Vassilopoulou S; Tsiamis E; Tsioufis K J Thromb Thrombolysis 2021[Oct]; 52 (3): 889-897 PMID33638018show ga Sickle cell disease (SCD) is an inherited monogenic hemoglobinopathy characterized by formation of sickle erythrocytes under conditions of deoxygenation. Sickle erythrocytes can lead to thrombus formation and vaso-occlusive episodes that may result in hemolytic anemia, pain crisis and multiple organ damage. Moreover, SCD is characterized by endothelial damage, increased inflammatory response, platelet activation and aggravation, and activation of both the intrinsic and the extrinsic coagulation pathways. Cerebrovascular events constitute an important clinical complication of SCD. Children with SCD have a 300-fold higher risk of acute stroke and by the age of 45 about 25% of patients have suffered an overt stoke. Management and prevention of stroke in patients with SCD is not well defined. Moreover, the presence of patent foramen ovale (PFO) increases the risk of the occurrence of an embolic cerebrovascular event. The role of PFO closure and antiplatelet or anticoagulation therapy has not been well investigated. Moreover, during COVID-19 pandemic and taking into account the increased rates of thrombotic events and the difficulties in blood transfusion, management of SCD patients is even more challenging and difficult, since data are scarce regarding stroke occurrence and management in this specific population in the COVID-19 era. This review focuses on pathophysiology of stroke in patients with SCD and possible treatment strategies in the presence of PFO. |Anemia, Sickle Cell/*complications/diagnosis/physiopathology/therapy[MESH] |COVID-19/complications[MESH] |Foramen Ovale, Patent/*complications/diagnosis/physiopathology/therapy[MESH] |Humans[MESH] |Primary Prevention[MESH] |Prognosis[MESH] |Recurrence[MESH] |Risk Assessment[MESH] |Risk Factors[MESH] |Secondary Prevention[MESH]Stroke and presence of patent foramen ovale in sickle cell disease (epmc).pdf DeepDyve Pubget Overpricing